ArticleBMC primary care2025
Performance evaluation of a point of care capillary blood test for C-reactive protein in community healthcare.
Article in BMC primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotics are often prescribed without a C-Reactive Protein (CRP) level, an inflammatory marker used to guide treatment decisions, due to delays in obtaining laboratory results. We evaluated a novel point of care testing (POCT) device that measures CRP within minutes using a small capillary blood sample obtained via finger prick, in community healthcare settings.
methodPatients in the community having blood samples taken for CRP measurement provided finger prick capillary blood in children and venous blood in adults, who also provided an additional capillary sample. All capillary samples were tested using the LumiraDX™ POCT device, which provided a quantitative CRP measurement within four minutes. Venous samples from adults and the same capillary samples from children were then tested using a standard laboratory method.
resultsA total of 161 patients agreed to measurements by the two methods. CRP levels as assessed by the laboratory method ranged from 0.9 to 382 mg/L, and 5.3 to 232.1 mg/L by POCT. There was a good correlation between results of the standard laboratory method and the POCT assay for CRP (r = 0.97), with a mean bias of -11.3 (slope 0.73, intercept 3.9 mg/L). Of the 161 patients tested, 57 gave CRP results outside the limits of quantitation of the POCT assay and were not included in the regression and bias analysis.
conclusionThe LumiraDX™ POCT device demonstrates sufficient accuracy in measuring CRP levels from finger prick capillary blood. The availability of this technology across community healthcare settings will improve the assessment of infection and support more precise antibiotic prescribing.
trial registrationACCom/SE/202,324/01 (Date of registration 17/08/2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.